Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04300244
Title Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Aslaug Helland
Indications

malignant pleural mesothelioma

Therapies

Ipilimumab + Nivolumab + UV1 Telomerase peptide vaccine

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.